Janssen R&D Ireland Share Participation Scheme

The study aims to characterize the cardiac safety of different treatment regimens of daratumumab, cyclophosphamide, bortezomib, and dexamethasone (DVCd) (Arm A: daratumumab + immediate combined VCd treatment, Arm B: daratumumab + delayed combined VCd treatment) in patients with newly diagnosed systemic AL amyloidosis with cardiac involvement and to identify potential risk prevention strategies for cardiac toxicity (Cohort 1); to characterize the pharmacokinetics of daratumumab SC in racial and ethnic minority populations (including black or African American subjects) with newly diagnosed systemic AL amyloidosis receiving D-VCd (Cohort 2).